Loading organizations...
Key people at ReMederi.
ReMederi provides streamlined access to medicinal cannabis products, offering scientific education and support for professionals and patients. The company enhances treatment predictability and efficacy through precise titration and dosage guidelines. It also utilizes advanced methodologies, like nanotechnology, to improve product bioavailability and stability.
Established in 2019 by Fabrizio Postiglione and Marcella Merigo, ReMederi arose from the critical need for accessible, scientifically sound medicinal cannabis solutions. The founders identified a significant information gap, aiming to responsibly integrate these therapies into standard medical practice. Their insight empowered professionals and patients to confidently engage with these evolving treatment options.
ReMederi primarily serves healthcare professionals prescribing medicinal cannabis, and patients using these treatments. Its vision focuses on improving public health by connecting stakeholders across the medicinal cannabis ecosystem. It cultivates an informed community, promoting wider and safer adoption of cannabis and integrative medicine for therapeutic applications.
Key people at ReMederi.
ReMederi is a Brazilian health company focused on medical cannabis, enabling legal access to cannabis-based products, services, and education to improve quality of life for patients.[1][2] It serves patients with medical prescriptions, healthcare professionals, and businesses by simplifying importation processes under ANVISA regulations (recognized since 2015 and updated via RDC nº660/2022), providing certified GMP products, scientific education, and streamlined support from consultation to delivery.[1][2] The company addresses challenges in prescribing, accessing, and investing in medical cannabis, emphasizing care, science-backed knowledge, safety, and ease of use, which drives its growth in Brazil's emerging market.[1][2]
ReMederi was founded in 2018 by Fabrizio Postiglione, stemming from his personal pain experience that highlighted unmet needs in medical cannabis access.[1] This personal motivation led to the creation of a global health company tailored to Brazil's regulatory landscape, where ANVISA first allowed cannabis product importation in 2015.[1][2] Early traction built on simplifying complex processes for patients and doctors, evolving into a comprehensive platform with certified products, education for prescribers, and global networking for businesses.[1][2]
ReMederi rides the global medical cannabis wave in Brazil, capitalizing on ANVISA's 2015 legalization of imports and 2022 updates that expand access amid rising demand for alternative therapies.[2] Timing aligns with growing scientific validation of cannabis for various conditions, market maturation, and health tech trends emphasizing patient-centric digital platforms for regulated substances.[1][2] It influences the ecosystem by bridging gaps in education and logistics, empowering prescribers, supporting patients, and fostering business investment in cannabis—accelerating adoption in a developing market.[1][2]
ReMederi is poised for expansion as Brazil's medical cannabis market matures, potentially scaling education tools, product portfolios, and B2B networking amid regulatory evolution and rising prescriptions.[1][2] Trends like digital health integration, international partnerships, and evidence-based advocacy will shape its path, enhancing influence in Latin America's cannabis ecosystem. This positions it to transform quality-of-life access, building directly on its founder-driven mission.[1][2]
